Module 6. Managing and Treating MDS-related Anemia
What is “refractory anemia” and “primary anemia”? Are these terms still in use?
MDS experts, Dr Rafael Bejar and Dr Casey O’Connell address what is meant by “refractory anemia” and “primary anemia” and explain that these terms are becoming more and more outdated. In the past, “refractory anemia” was used to refer to an anemia that didn’t respond to any known treatment at the time. Nowadays, with MDS being better understood, refractory anemia refers to anemia that a patient has that is otherwise unexplained but may be due to MDS.
Share with family and friends:
Click here to take our Myelodysplastic Syndromes (MDS) SURVEY Your feedback is important to us! We will use your feedback to develop future areas of content about MDS which will help other patients, caregivers and families.
This educational activity has been developed by
the Myelodysplastic Syndromes Foundation, Inc and Mechanisms in Medicine Inc.
This activity is supported by an educational grant from Acceleron Pharma, Celgene Corporation, Jazz Pharmaceuticals, Novartis, and Takeda Oncology.
This website is part of the Animated Patient™ series developed by Mechanisms in Medicine Inc., to provide highly visual formats of learning for patients to improve their understanding, make informed decisions, and partner with their healthcare professionals for optimal outcomes.